The Gulf conflict has disrupted global supply chains, pushed...
REITs have changed the way commercial real estate is owned a...
What really powers the cloud? Behind every Google search, A...
What really powers the cloud? Behind every Google search, A...
Luxury real estate is one of the most talked-about segments ...
The Sandur Manganese & Iron Ores Limited (SMIORE) has entered the medical devices and consumables business through its wholly owned subsidiary, Royal Sandur MedTech Private Limited, which has leased 6.2 acres at the Andhra Pradesh MedTech Zone in Visakhapatnam. The 33-year lease includes infrastructure for road access, power, water and effluent management. The subsidiary also has office space at the World Trade Center AMTZ. The company plans to establish a manufacturing unit at the site, but details about capital expenditure, products and project timelines are yet to be announced.
The Sandur Manganese & Iron Ores Limited (SMIORE) has entered the medical devices and consumables sector through its wholly owned subsidiary, Royal Sandur MedTech Private Limited, which has leased 6.2 acres of land at the Andhra Pradesh MedTech Zone (AMTZ) in Visakhapatnam to establish a manufacturing unit.
The lease deed was executed on October 19, 2026, between Royal Sandur MedTech and Andhra Pradesh MedTech Zone Limited, a Government of Andhra Pradesh undertaking that owns and operates the medical technology park. The subsidiary has also leased office space at the World Trade Center AMTZ to support project development.
The leased land measures approximately 25,090 square metres and comes with road access, power, water and effluent infrastructure provided by AMTZ. The lease tenure is 33 years from the date of execution. Royal Sandur MedTech will also have the exclusive right to convert its leasehold rights into freehold ownership after 10 years from the commissioning of its business.
The move forms part of SMIORE's diversification strategy as the company seeks to expand beyond its existing mining and metals operations. The company said details of the project's capital expenditure and implementation timelines would be announced later.
Bahirji A. Ghorpade, managing director of SMIORE, said the medical devices and consumables sector offered opportunities to expand domestic manufacturing. He added that AMTZ's shared manufacturing and scientific facilities would provide a platform for a new entrant to develop capabilities while managing capital requirements. Securing the land marked the first concrete step in the company's expansion into the sector, he said.
Dr Jitendra Sharma, managing director and founder CEO of AMTZ, welcomed Royal Sandur MedTech to the facility. He said the investment reflected growing confidence among Indian companies in the country's medical technology manufacturing capabilities and reinforced AMTZ's role in supporting innovation, domestic production and global competitiveness.
SMIORE has more than seven decades of operating experience in mining and commodity production. Its existing businesses include manganese and iron ore mining, ferroalloys, and coke and energy. The company also has a presence in the specialty steel sector through its material subsidiary, Royal Sandur Metals Private Limited, which operates in the special bar quality steel segment.
The entry into medical devices and consumables expands the Royal Sandur Group's business portfolio beyond its established mining, metals and steel operations. However, the company has not yet disclosed the planned investment, products to be manufactured at the Visakhapatnam facility or the expected date of commencement of production.
The planned manufacturing facility marks an expansion of Royal Sandur Group's business interests into medical technology, alongside its existing mining, ferroalloys, coke, energy and steel operations. AMTZ's shared infrastructure provides the proposed unit with access to facilities required for medical technology manufacturing. The next key details will be the company's investment commitment, the products it intends to manufacture and its construction and production schedule. Until these are announced, the scale and expected contribution of the new business to SMIORE's operations remain unclear.
Source PTI
17th Nov, 2026
16th Nov, 2026
15th Nov, 2026
15th Nov, 2026
15th Nov, 2026